AbbVie acquires Allergan for $63B foreseeing Humira patent expiration
Category: #health  By Mateen Dalal  Date: 2019-06-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

AbbVie acquires Allergan for $63B foreseeing Humira patent expiration

American biopharmaceutical firm AbbVie Inc has reportedly announced its decision to acquire Botox-maker Allergan Plc in a $63 billion deal.

Apparently, this move would hand over the control of the profitable wrinkle remedy Botox to AbbVie, providing it enough time to explore new business opportunities before its top-selling arthritis drug Humira faces expiration of U.S. patents.

Evidently, Humira, one of the world’s bestselling drug, had managed to make $20 billion in 2018 but now faces rivalry from its cheaper versions in Europe. United States has been its most lucrative market so far, but the firm must tackle the expiration of its patents, which last until 2023.

Richard Gonzalez, AbbVie CEO and chairman, stated that the acquisition of Allergen could proceed on account of the funds raised by Humira. He admitted that Humira is helping to invest in assets that would substitute it over the long term. Gonzalez seems to be planning to lead the merged business through 2023.

Prominent in the list of those assets to be acquired is Allergan’s Botox, a purified form botulinum toxin that smoothens wrinkles and frown lines around the eyes and on the forehead by paralyzing various muscles. The drug is also known to handle an overactive bladder, treat chronic migraine headaches and provide other remedial benefits.

Citing reliable sources, when used as a cosmetic medication, patients need to pay for the drug out of pocket, shielding it from pricing burden that government health organizations and health insurers put on prescription drugs. Gonzalez also admitted that he does not anticipate another version of Botox.

Damien Conover, Morningstar analyst said that growing concerns regarding AbbVie’s future growth following biosimilar competition to Humira in 2023 would be moderately eased with the additional set of assets Allergan will offer.

According to Refinitiv data, Botox had close to $3.6 billion sales in 2018, with $1.55 billion coming from cosmetic applications. Both cosmetic and therapeutic Botox are anticipated to flourish, with expert analysts estimating total sales of about $3.9 billion in 2019 and nearing $6 billion by 2025.

 

Source Credits: https://www.reuters.com/article/us-allergan-m-a-abbvie/abbvie-looks-beyond-humira-with-63-billion-deal-for-botox-maker-allergan-idUSKCN1TQ15X

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Nuclear Battery Market a Comprehensive Analysis Competitive Market Share & Forecast
Nuclear Battery Market a Comprehensive Analysis Competitive Market Share & Forecast
By Mateen Dalal

Nuclear Battery Market size will witness growth on account of increasing demand for efficient power generation technologies coupled with improved operational efficiency. Ability of these batteries to generate power in diverse voltage levels based on ...

MediciNova confirms Phase 3 trial of ibudilast in progressive MS
MediciNova confirms Phase 3 trial of ibudilast in progressive MS
By Mateen Dalal

Ibudilast could be the best-in-disease drug for MS patients with unmet medical needs MediciNova, Inc., a biopharmaceutical company that develops novel therapeutics and is traded on Tokyo Stock Exchange’s JASDAQ Market and on NASDAQ Global Mark...

CMIC becomes Align Clinical CRO member to enhance trial partnerships
CMIC becomes Align Clinical CRO member to enhance trial partnerships
By Mateen Dalal

The teaming up of CMIC with other companies will improve the collaboration and execution of clinical studies CMIC Group, a leading Japanese Contract Research Organization (CRO) that provides complete range of pharmaceutical drug services, recently a...